Post-Marketing Safety Monitoring of a New Group B Meningococcal Vaccine in New Zealand, 2004-2006

 Abstract

New Zealand introduced a new outer membrane vesicle vaccine in 2004 to combat an epidemic of group B meningococcal disease. An Independent Safety Monitoring Board oversaw intensive safety monitoring, which included hospital surveillance, health professional reporting (passive and active) and mortality monitoring. With over three million doses administered to individuals aged under 20 years, the monitoring results provide consistent evidence supporting the vaccine’s safety.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
196 - 204
doi
10.4161/hv.3.5.4458
Type
Research Paper
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Post-Marketing Safety Monitoring of a New Group B Meningococcal Vaccine in New Zealand, 2004-2006